Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Share-based Compensation (2021 - 2025)

Bioventus (BVS) has disclosed Share-based Compensation for 5 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 70.63% year-over-year to $3.4 million, compared with a TTM value of $12.7 million through Dec 2025, down 4.53%, and an annual FY2025 reading of $12.7 million, down 4.53% over the prior year.
  • Share-based Compensation was $3.4 million for Q4 2025 at Bioventus, up from $3.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.1 million in Q4 2021 and bottomed at -$2.7 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $3.3 million, with a median of $3.3 million recorded in 2022.
  • The sharpest move saw Share-based Compensation plummeted 159.19% in 2023, then skyrocketed 311.46% in 2024.
  • Year by year, Share-based Compensation stood at $6.1 million in 2021, then crashed by 43.82% to $3.4 million in 2022, then crashed by 48.28% to $1.8 million in 2023, then grew by 13.58% to $2.0 million in 2024, then soared by 70.63% to $3.4 million in 2025.
  • Business Quant data shows Share-based Compensation for BVS at $3.4 million in Q4 2025, $3.2 million in Q3 2025, and $3.6 million in Q2 2025.